openPR Logo
Press release

Sialorrhea Treatment Market 2034: EMA, PDMA, FDA Approvals, Medication, Clinical Trials, Revenue, Statistics, Therapies, Prevalence, Companies by DelveInsight

05-14-2025 07:09 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Sialorrhea Treatment Market

Sialorrhea Treatment Market

(Albany, USA) DelveInsight's "Sialorrhea Market Insight, Epidemiology and Market Forecast - 2034" report delivers an in-depth analysis of Sialorrhea epidemiology, market, and clinical development in Sialorrhea. In addition to this, the report provides historical and forecasted epidemiology and market data as well as a detailed analysis of the Sialorrhea market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

The Sialorrhea market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Sialorrhea market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Sialorrhea treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Sialorrhea market.

Discover which therapies are expected to grab the Sialorrhea Market Share @ Sialorrhea Market Outlook- https://www.delveinsight.com/sample-request/sialorrhea-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Takeaways from the Sialorrhea Market Report
• In 7MM, the United States accounts for the highest number of prevalent cases of Sialorrhea in 2023.
• In the United States around 3,36,800 cases of Chronic Sialorrhea in Parkinson's disease were present in 2023.
• Amongst EU4 and the UK, Germany had the highest prevalent population of Sialorrhea, followed by the United Kingdom. On the other hand, Spain had the lowest diagnosed prevalent population in 2023.
• The leading Sialorrhea Companies such as Orient Pharma Co., Ltd, Supernus Pharmaceuticals, Inc., NeuroHealing Pharmaceuticals Inc., Merz Pharmaceuticals GmbH, Solstice Neurosciences, and others.
• Promising Sialorrhea Pipeline Therapies such as NT 201, Oral Glycopyrrolate Liquid, NH004 tropicamide, MYOBLOC, and others.

Stay ahead in the Sialorrhea Therapeutics Market with DelveInsight's Strategic Report @ Sialorrhea Market Outlook- https://www.delveinsight.com/sample-request/sialorrhea-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Sialorrhea Epidemiology Segmentation in the 7MM
• Total Sialorrhea Prevalent Cases of Selected Indications
• Total Prevalent Cases of Sialorrhea in Selected Indications
• Total Prevalent Cases of Chronic Sialorrhea in Selected Indications

Download the report to understand which factors are driving Sialorrhea Epidemiology trends @ Sialorrhea Prevalence- https://www.delveinsight.com/sample-request/sialorrhea-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Sialorrhea Marketed Drug
• MYOBLOC (rimabotulinumtoxinB): US WorldMeds
MYOBLOC is the first and only FDA-approved botulinum toxin B for the treatment of chronic Sialorrhea (excessive drooling) in adults. MYOBLOC is an acetylcholine release inhibitor that blocks cholinergic transmission at the neuromuscular and salivary neuroglandular junction by inhibiting the release of acetylcholine from peripheral cholinergic nerve terminals. MYOBLOC was first approved by the US Food and Drug Administration (FDA) for cervical dystonia in December 2000. US WorldMeds submitted a supplemental biologics license application (sBLA) for the drug to the FDA for the treatment of chronic Sialorrhea in October 2018. MYOBLOC was approved for the condition in August 2019. The drug is marketed in Europe by US WorldMeds' subsidiary Sloan Pharma along with Eisai, under the brand name NEUROBLOC, for the treatment of cervical dystonia. Eisai develops and markets the drug in Japan under the brand name NERBLOC for the same indication.

• XEOMIN: Merz Pharmaceuticals
XEOMIN (incobotulinumtoxinA) for injection is indicated for the treatment of Chronic Sialorrhea in patients 2 years of age and older. In July 2018, the US FDA approved XEOMIN for chronic or excessive drooling (Sialorrhea) in adult patients. In December 2020, Merz Therapeutics announced that the US FDA has approved a sBLA for XEOMIN for the treatment of patients aged 2 years and older with chronic Sialorrhea, or drooling. XEOMIN is the first and only FDA-approved neuromodulator with this indication and was granted a priority review designation upon acceptance by the FDA. XEOMIN gained European approval for treating Chronic Sialorrhea in children in 2021, while its approval for adult patients dates back to 2019.

Transitional Cell Carcinoma Treatment Landscape
Treating Sialorrhea is a difficult process and requires group efforts. The aim is to reduce or stop excess salivation. Current treatment practices vary among practitioners. Traditional treatment options include daily oral medications to diminish saliva production, periodic injections of a medication called Botox for a temporary reduction in saliva production, or a variety of open surgical procedures to remove some salivary glands or disconnect others from the mouth. Thus, the treatment ranges from conservative to more invasive treatment methods. Changes in diet or habits, oral-motor exercises, intra-oral devices such as palatal training devices, and medical treatments such as medication or botulinum toxin injections constitute conservative methods of treatment.

To learn more about Sialorrhea treatment guidelines, visit @ Sialorrhea Treatment Market Landscape- https://www.delveinsight.com/sample-request/sialorrhea-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Sialorrhea Market Outlook
Anticholinergic agents like glycopyrrolate are commonly used, with oral solutions like CUVPOSA gaining popularity due to their acceptability among children. Additionally, botulinum toxins, particularly Xeomin, have emerged as effective alternatives with fewer side effects, gaining FDA approval in the US and EMA approval in Europe. Market-wise, the landscape has seen significant shifts, especially with the introduction of MYOBLOC and other botulinum toxin formulations. These approved treatments are expected to dominate the market, reducing the reliance on off-label use of unlicensed products. Furthermore, ongoing research and development, including promising candidates like NT004, and OP-014 indicate a future trend towards targeted therapies with improved efficacy and reduced side effects, shaping a more optimistic outlook for Sialorrhea management.

Learn more about the FDA-approved drugs for Sialorrhea @ Drugs for Sialorrhea Treatment-https://www.delveinsight.com/sample-request/sialorrhea-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of the Sialorrhea Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Sialorrhea Companies- Orient Pharma Co., Ltd, Supernus Pharmaceuticals, Inc., NeuroHealing Pharmaceuticals Inc., Merz Pharmaceuticals GmbH, Solstice Neurosciences, and others.
• Sialorrhea Pipeline Therapies- NT 201, Oral Glycopyrrolate Liquid, NH004 tropicamide, MYOBLOC, and others.
• Sialorrhea Market Dynamics: Sialorrhea Market Drivers and Barriers
• Sialorrhea Market Access and Reimbursement, Unmet Needs and Future Perspectives

Discover more about Sialorrhea Drugs in development @ Sialorrhea Clinical Trials Assessment- https://www.delveinsight.com/sample-request/sialorrhea-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Content
1. Key Insights
2. Sialorrhea Report Introduction
3. Executive Summary of Sialorrhea
4. Key Events
5. Sialorrhea Epidemiology and Market Forecast Methodology
6. Sialorrhea Market Overview at a Glance
7. Disease Background and Overview: Sialorrhea
8. Sialorrhea Treatment and Management
9. Sialorrhea Epidemiology and Patient Population
10. Sialorrhea Patient Journey
11. Sialorrhea Marketed Drugs
12. Sialorrhea: 7MM Analysis
13. Sialorrhea Unmet Needs
14. Sialorrhea SWOT Analysis
15. Sialorrhea KOL Views
16. Sialorrhea Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

Related Reports:
• Trigeminal Neuralgia Market Size: https://www.delveinsight.com/report-store/chronic-pain-market
• Ventricular Fibrillation Market: https://www.delveinsight.com/report-store/electrophysiology-devices-market
• Adamantinoma Market: https://www.delveinsight.com/blog/bone-cancer-treatment-market
• Healthcare Subscription Models: https://www.delveinsight.com/blog/subscription-model-in-healthcare
• Healthcare Competitive Benchmarking: https://www.delveinsight.com/consulting/competitive-benchmarking-services
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Benefits Of Robotics In Healthcare: https://www.delveinsight.com/blog/robotics-in-healthcare
• Wound Irrigation Systems Market: https://www.delveinsight.com/report-store/wound-irrigation-systems-market?utm_source=Medgadget&utm_medium=pressrelease&utm_campaign=kupr
• Pulse Oximeter Market: https://www.delveinsight.com/report-store/pulse-oximeters-market
• Gaucher Disease Market: https://www.delveinsight.com/report-store/gauchers-disease-market
• Anti-cd274 Pd-l1 Antibody Pipeline: https://www.delveinsight.com/report-store/pd-1-and-pd-l1-inhibitors-competitive-landscape
• Apheresis Market: https://www.delveinsight.com/report-store/apheresis-market
• Atherectomy Devices Market: https://www.delveinsight.com/report-store/atherectomy-devices-market
• Hearing Implants Market: https://www.delveinsight.com/report-store/hearing-implants-market
• Menopause Market: https://www.delveinsight.com/report-store/menopause-market
• Ophthalmic Imaging Equipment Market: https://www.delveinsight.com/report-store/ophthalmic-imaging-equipment-market
• Aortic Aneurysm Stent Grafts Market: https://www.delveinsight.com/report-store/aortic-aneurysm-stent-grafts-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Chronic Lymphocytic Leukemia Cll Market: https://www.delveinsight.com/report-store/chronic-lymphocytic-leukemia-cll-market
• Healthcare Due Diligence Services: https://www.delveinsight.com/consulting/due-diligence-services
• Pressure Ulcers Market: https://www.delveinsight.com/report-store/pressure-ulcers-market
• Pulse Oximeters Market: https://www.delveinsight.com/report-store/pulse-oximeters-market
• Diabetic Foot Ulcers Dfus Market: https://www.delveinsight.com/report-store/diabetic-foot-ulcers-dfus-market
• Energy Based Aesthetic Devices Market: https://www.delveinsight.com/report-store/energy-based-aesthetic-devices-market
• Hepatitis B Virus Market: https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-market
• Minimal Residual Disease Market: https://www.delveinsight.com/report-store/minimal-residual-disease-market
• Vertigo Market: https://www.delveinsight.com/report-store/vertigo-market
• Chronic Hepatitis B Virus Market: https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-market
• Neuroprosthetics Market: https://www.delveinsight.com/blog/neuroprosthetics-market-analysis
• Non Alcoholic Fatty Liver Disease Nafld Market: https://www.delveinsight.com/report-store/non-alcoholic-fatty-liver-disease-nafld-market
• Palmar Hyperhidrosis Market: https://www.delveinsight.com/report-store/palmar-hyperhidrosis-market
• Acute Pain Market: https://www.delveinsight.com/report-store/acute-pain-market
• Automated External Defibrillators Market: https://www.delveinsight.com/report-store/external-defibrillators-market
• Dysthymia Market: https://www.delveinsight.com/report-store/persistent-depressive-disorder-market?utm_source=globenewswire&utm_medium=pressrelease&utm_campaign=spr
• Interbody Cages Market: https://www.delveinsight.com/report-store/interbody-cages-market
• Osteoarthritis Market: https://www.delveinsight.com/report-store/knee-osteoarthritis-market
• Palmar Hyperhidrosis Market Size: https://www.delveinsight.com/report-store/palmar-hyperhidrosis-market
• Wet-age Related Macular Degeneration Market: https://www.delveinsight.com/report-store/wet-age-related-macular-degeneration-wet-amd-market
• X Linked Hypophosphatemia Market: https://www.delveinsight.com/report-store/x-linked-hypophosphatemia-market
• Absssi Market Size: https://www.delveinsight.com/report-store/acute-bacterial-skin-and-skin-structure-infections-market
• Age-related Macular Degeneration Market: https://www.delveinsight.com/report-store/age-related-macular-degeneration-amd-market
• Androgenetic Alopecia Market: https://www.delveinsight.com/report-store/androgenetic-alopecia-market
• Arthroscopy Devices Market: https://www.delveinsight.com/report-store/arthroscopy-devices-market
• Artificial Kidney Market: https://www.delveinsight.com/report-store/artificial-kidney-market
• Carpal Tunnel Syndrome Market: https://www.delveinsight.com/report-store/carpal-tunnel-syndrome-market
• Central Pain Syndrome Market: https://www.delveinsight.com/report-store/central-pain-syndrome-market
• Cough Assisted Device Market: https://www.delveinsight.com/report-store/cough-assist-devices-market
• Duchenne Muscular Dystrophy Market: https://www.delveinsight.com/blog/duchenne-muscular-dystrophy-market
• Hearing Aid Devices Market: https://www.delveinsight.com/report-store/audiology-devices-market
• Neurovascular Devices Market: https://www.delveinsight.com/report-store/neurovascular-devices-interventional-neurology-market
• Prefilled Syringes Market: https://www.delveinsight.com/report-store/prefilled-syringes-market
• Xerostomia Market: https://www.delveinsight.com/report-store/xerostomia-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/ats-conference-coverage

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Sialorrhea Treatment Market 2034: EMA, PDMA, FDA Approvals, Medication, Clinical Trials, Revenue, Statistics, Therapies, Prevalence, Companies by DelveInsight here

News-ID: 4016533 • Views:

More Releases from DelveInsight Business Research

Hepatic Encephalopathy Market Expected to Gain Momentum Through 2034, According to DelveInsight
Hepatic Encephalopathy Market Expected to Gain Momentum Through 2034, According …
DelveInsight's "Hepatic Encephalopathy Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Hepatic Encephalopathy, historical and forecasted epidemiology as well as the Hepatic Encephalopathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. To Know in detail about the Hepatic Encephalopathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hepatic Encephalopathy Market Forecast https://www.delveinsight.com/sample-request/hepatic-encephalopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the
Myopia Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals
Myopia Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Myopia pipeline constitutes 8+ key companies continuously working towards developing 10+ Myopia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Myopia Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Myopia Market. The Myopia Pipeline report embraces in-depth
Dravet Syndrome Market Trends Point to Steady Growth Ahead by 2034, DelveInsight Analysis Reveals
Dravet Syndrome Market Trends Point to Steady Growth Ahead by 2034, DelveInsight …
DelveInsight's "Dravet Syndrome Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Dravet Syndrome, historical and forecasted epidemiology as well as the Dravet Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Dravet Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Dravet Syndrome Market Forecast https://www.delveinsight.com/sample-request/dravet-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the
Axial Spondyloarthritis Market Dynamics Indicate Upward Trajectory Through 2034, Reports DelveInsight
Axial Spondyloarthritis Market Dynamics Indicate Upward Trajectory Through 2034, …
DelveInsight's "Axial Spondyloarthritis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Axial Spondyloarthritis, historical and forecasted epidemiology as well as the Axial Spondyloarthritis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Axial Spondyloarthritis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Axial Spondyloarthritis Market Forecast https://www.delveinsight.com/sample-request/axial-spondyloarthritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the

All 5 Releases


More Releases for Sialorrhea

Sialorrhea Treatment Market Size Report 2034: Major Companies, Emerging Drugs, C …
DelveInsight's "Sialorrhea Market Insight, Epidemiology and Market Forecast - 2034" report delivers an in-depth analysis of Sialorrhea epidemiology, market, and clinical development in Sialorrhea. In addition to this, the report provides historical and forecasted epidemiology and market data as well as a detailed analysis of the Sialorrhea market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan. Discover which therapies are expected to
Chronic Sialorrhea Market to Rise as Neurological Treatment Innovations Advance …
📊 Chronic Sialorrhea Market Snapshot 2025-2032 Chronic Sialorrhea Market is projected to reach USD 672 Million by 2032, with a CAGR of 6.1% during the forecast period 2025 to 2032. Coherent Market Insights unveils its latest data-driven Chronic Sialorrhea Market Research Report featuring transformative insights into the U.S. Chronic Sialorrhea Market. Spanning from 2025 to 2032, this report offers granular forecasts, payer-provider models, and supply chain intelligence. As the U.S. healthcare ecosystem
Chronic Sialorrhea Market Size Forecasted To Achieve 0.97 Billion By 2029 With S …
We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries. What Is the Chronic Sialorrhea Market Size and Projected Growth Rate? The market size for chronic sialorrhea has significantly expanded over the recent past. Its projected growth is from $0.72 billion in 2024 to an elevated figure of $0.76 billion in 2025, with a CAGR of 6.5%. Factors such as an increased
Global Chronic Sialorrhea Market Projected to Surpass $0.97 Billion by 2029 with …
What combination of drivers is leading to accelerated growth in the chronic sialorrhea market? The increasing prevalence of neurodegenerative disorders is expected to drive the growth of the chronic sialorrhea market. Neurodegenerative diseases like Parkinson's disease and amyotrophic lateral sclerosis (ALS) lead to progressive neuron degeneration, and a common complication is chronic sialorrhea (excessive drooling). As these diseases become more prevalent, particularly with the aging population, treatments to manage chronic sialorrhea
Sialorrhea Market Size by Growth Rate, Business Challenges, Competitors, and For …
The global sialorrhea market is projected to grow from an estimated USD 2.25 billion in 2024 to USD 3.64 billion by 2033, at a compound annual growth rate (CAGR) of 5.50%. The market is experiencing significant growth due to the increasing prevalence of neurodegenerative disorders such as Parkinson's disease, amyotrophic lateral sclerosis (ALS), and Alzheimer's disease. According to the World Health Organization (WHO), nearly 50 million people worldwide are affected by
Sialorrhea Treatment Market Global Rising Demand & Huge Scope Till 2030
A new market study report by The Insight Partners on the Sialorrhea Treatment Market has been released with reliable information and accurate forecasts for a better understanding of the current and future market scenarios. The report offers an in-depth analysis of the global market, including qualitative and quantitative insights, historical data, and estimated projections about the market size and share in the forecast period. Get PDF Sample Report +